Analyst Ratings for Travere Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Travere Therapeutics (NASDAQ:TVTX) within the last quarter, with 2 bullish, 3 somewhat bullish, and 1 indifferent. The average 12-month price target for the company is $27.5, a decrease of 12.22% from the previous average price target of $31.33.
September 06, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mixed analyst ratings and a decreased price target could impact Travere Therapeutics' stock price.
The mixed analyst ratings indicate uncertainty about the company's performance. The decrease in the average price target suggests that analysts have lowered their expectations for the company's stock price, which could negatively impact investor sentiment and lead to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100